Is MDMA Legal in the US? Federal Status, Clinical Access, and Research Pathways
MDMA remains illegal for general use in the United States under federal law, classified as a Schedule I substance. There is no approved clinical use; access is limited to research trials.
Is MDMA Legal in the US? The Short Answer
No, MDMA (3,4-methylenedioxymethamphetamine), commonly known as "ecstasy" or "molly," is not legal for general use in the United States. Under federal law, MDMA is classified as a Schedule I controlled substance under the Controlled Substances Act (CSA), 21 U.S.C. § 812. This means it is considered to have a high potential for abuse, no currently accepted medical use, and a lack of accepted safety for use under medical supervision. There are no FDA-approved clinical uses for MDMA as of this writing, and it is illegal to possess, distribute, or manufacture MDMA outside of strictly regulated research settings. This article is for informational purposes only and does not constitute legal advice.
Federal Scheduling: The Legal Foundation
The Controlled Substances Act (CSA) is the primary federal law governing drug regulation in the US. Substances are classified into five schedules based on their potential for abuse, accepted medical use, and safety profile. Schedule I is the most restrictive category. MDMA has been listed as Schedule I since 1985, following an emergency scheduling by the Drug Enforcement Administration (DEA). This places it alongside substances like heroin and LSD, and means:
- No accepted medical use: The Food and Drug Administration (FDA) has not approved MDMA for any therapeutic indication.
- High potential for abuse: The DEA and Department of Health and Human Services (HHS) have determined that MDMA poses significant risks of misuse.
- Severe restrictions on research: Research with MDMA requires special DEA registration, security protocols, and oversight.
For more on the legal landscape, see our psychedelic law guide.
FDA Review and the Status of Medical MDMA
In recent years, there has been significant interest in the potential therapeutic use of MDMA, especially for post-traumatic stress disorder (PTSD). However, as of August 2024, the FDA declined to approve the first New Drug Application (NDA) for MDMA-assisted therapy submitted by Lykos Therapeutics (formerly MAPS Public Benefit Corporation). The FDA cited the need for an additional Phase 3 clinical trial to address outstanding questions about efficacy and safety. This means there is no FDA-approved clinical use for MDMA in the US at this time.
Access to MDMA for therapy or treatment is not permitted outside of clinical research trials. All use outside these settings remains illegal under federal law. For a broader view of the research landscape, visit our psychedelic research landscape page.
MDMA in Clinical Trials: How Is Access Possible?
While MDMA is not legal for general or medical use, it can be studied in controlled research settings. Researchers must obtain:
- DEA Schedule I research registration
- Institutional Review Board (IRB) approval
- FDA Investigational New Drug (IND) authorization
Participants in these trials may receive MDMA under strict supervision, but this does not confer any legal right to access MDMA outside of the study. For more on research protocols and ethics, see our guides and briefing feed.
State and Local Law: Does It Make a Difference?
Some US cities and states have moved to deprioritize or decriminalize certain psychedelic substances, but MDMA remains illegal under federal law everywhere in the US. Even in jurisdictions with local reforms, federal law preempts local ordinances, and MDMA possession, sale, or use can still be prosecuted federally. There is no state-level medical program for MDMA, unlike cannabis or, in some cases, psilocybin.
For a comparison with other psychedelics, see our psychedelic policy briefing.
International Context and Future Outlook
Globally, there is growing interest in the medical use of MDMA. For example, in September 2026, New Zealand approved MDMA for the treatment of severe PTSD, setting a precedent for regulated clinical use. However, these changes do not affect US law or policy. Any future approval in the US would require successful completion of further clinical trials and subsequent FDA review. Until then, MDMA's Schedule I status remains unchanged.
For ongoing updates and analysis, explore our psychedelic start page and briefing feed.
What Should You Do Next?
If you are a researcher, clinician, or investor interested in MDMA, it is essential to understand the current legal and regulatory framework. Access is strictly limited to approved clinical trials. For more detailed guidance, see our legal overview, research landscape, and practical guides.